Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 18 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q1 2024
Institutional positions in Pharvaris N.V. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- −1 vs. Q4 2023
- Shares held
- 42.4M
- +1.68M (+4.1%) vs. Q4 2023
- Total value
- $980.5M
- −$162.5M (−14.2%) vs. Q4 2023
- New holders
- 6
- 12 more added
- Sold out
- 7
- 9 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 2,000 | $46.2K | 0.01% | +2,000 | New |
| BlackRock Inc. | 2,268 | $52.4K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 3,150 | $72.8K | 0.00% | +2,960+1,557.9% | Added |
| Bank of America Corp | 7,808 | $180.4K | 0.00% | +7,808 | New |
| Jump Financial, LLC | 11,700 | $270.4K | 0.01% | +11,700 | New |
| HighVista Strategies LLC | 16,750 | $387.1K | 0.14% | +16,750 | New |
| Hudson Bay Capital Management LP | 20,018 | $462.6K | 0.00% | −50,116−71.5% | Reduced |
| Millennium Management LLC | 20,527 | $474.4K | 0.00% | −167,989−89.1% | Reduced |
| Morgan Stanley | 29,041 | $671.1K | 0.00% | +6,553+29.1% | Added |
| Qube Research & Technologies Ltd | 30,138 | $696.5K | 0.00% | −2,180−6.7% | Reduced |
| Goldman Sachs Group Inc | 31,116 | $719.1K | 0.00% | +22,567+264.0% | Added |
| Geode Capital Management, LLC | 31,224 | $721.6K | 0.00% | +9,629+44.6% | Added |
| Manufacturers Life Insurance Company, The | 55,078 | $1.27M | 0.00% | 00.0% | Unchanged |
| Marshall Wace, LLP | 58,169 | $1.34M | 0.00% | −1,955−3.3% | Reduced |
| Walleye Capital LLC | 97,182 | $2.25M | 0.02% | +19,312+24.8% | Added |
| TD Asset Management Inc | 112,616 | $2.60M | 0.00% | +112,616 | New |
| Citadel Advisors LLC | 238,305 | $5.51M | 0.01% | +96,847+68.5% | Added |
| Sphera Funds Management Ltd. | 392,877 | $9.08M | 1.47% | +147,877+60.4% | Added |
| Soleus Capital Management, L.P. | 401,901 | $9.29M | 0.82% | +184,505+84.9% | Added |
| Sofinnova Investments, Inc. | 584,672 | $13.5M | 0.80% | +74,231+14.5% | Added |
| Rock Springs Capital Management LP | 752,924 | $17.4M | 0.44% | +752,924 | New |
| Price T Rowe Associates Inc | 757,915 | $17.5M | 0.00% | −84,783−10.1% | Reduced |
| 5AM Venture Management, LLC | 797,600 | $18.4M | 4.13% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 900,000 | $20.8M | 0.53% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 1,061,592 | $24.5M | 0.43% | +249,356+30.7% | Added |
| Novo Holdings A/S | 1,168,030 | $27.0M | 1.86% | −371,295−24.1% | Reduced |
| Cormorant Asset Management, LP | 1,711,460 | $39.6M | 1.74% | 00.0% | Unchanged |
| Commodore Capital LP | 1,725,000 | $39.9M | 2.67% | +925,000+115.6% | Added |
| Bain Capital Life Sciences Investors, LLC | 3,303,381 | $76.3M | 6.14% | −600,938−15.4% | Reduced |
| VR Adviser, LLC | 3,395,606 | $78.5M | 3.73% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,653,310 | $84.4M | 0.31% | −3,613−0.1% | Reduced |
| Foresite Capital Management IV, LLC | 4,038,842 | $93.3M | 47.16% | 00.0% | Unchanged |
| venBio Partners LLC | 4,289,304 | $99.1M | 35.17% | −630,200−12.8% | Reduced |
| FMR LLC | 5,192,984 | $120.0M | 0.01% | 00.0% | Unchanged |
| General Atlantic LLC | 7,531,252 | $174.0M | 4.04% | +1,375,000+22.3% | Added |
| Vivo Capital, LLC | 0 | $0 | 0.00% | −285,000−100.0% | Sold out |
| Blackstone Group Inc. | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −18,000−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −12,400−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −8,198−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −750−100.0% | Sold out |
| Piper Sandler & Co. | 0 | $0 | 0.00% | −181−100.0% | Sold out |